# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-334174
Filing Date
2026-08-05
Accepted
2026-08-05 10:30:38
Documents
71
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | mcrb-20260630.htm iXBRL | 10-Q | 2795332
2 | EX-10.1 | mcrb-ex10_1.htm | EX-10.1 | 43920
3 | EX-31.1 | mcrb-ex31_1.htm | EX-31.1 | 15244
4 | EX-31.2 | mcrb-ex31_2.htm | EX-31.2 | 15144
5 | EX-32.1 | mcrb-ex32_1.htm | EX-32.1 | 9489
6 | EX-32.2 | mcrb-ex32_2.htm | EX-32.2 | 9396
| Complete submission text file | 0001193125-26-334174.txt |  | 9502764

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | mcrb-20260630.xsd | EX-101.SCH | 1100072
75 | EXTRACTED XBRL INSTANCE DOCUMENT | mcrb-20260630_htm.xml | XML | 1613134

Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 261241824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)